A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Key facts
- Who runs it
- AbbVie
- Trial code
- Status
- Withdrawn
- Started
- 1 Jun 2023
- Ended
- 30 Apr 2024
- Type of study
- Observational
- Record updated
- 12 April 2024
- Why it stopped
- Strategic considerations
Who can take part
- Age
- 18 years to 89 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- The participant received a diagnosis for acute myeloid leukemia (AML)
- The participant was initiated on the studied line of therapy for previously untreated AML, as noted in the protocol
- The participant was treated with the studied line of therapy at least 28 days prior to date of data collection
- Information on the participant's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards
Who cannot take part
- The participant received the studied line of therapy as part of a clinical trial
- Participant received prior lines of therapy for AML
- The participant has a history of malignancies within 2 years prior to the studied line of therapy, other than AML, and with the exception of what is noted in the protocol
About the trial
What the trial wants to find out
Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax.
Read full original descriptionShow less
Data from up to 700 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 10 months.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months.
The group in the trial
- Participants Receiving Venetoclax
Participants with AML receiving venetoclax undergoing chart review.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Center-Based Chart Review Study to Assess Treatment Outcomes of Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
- Record updated
- 12 April 2024